PBS pathway to VENCLEXTA in 1L & R/R CLL: A step-by-step guide
Learn about the relevant PBS clinical criteria and codes when initiating VENCLEXTA in combination with obinutuzumab (1L CLL) or rituximab (R/R CLL).
CLL Fixed Duration Treatment Journey brochure
This explores the potential benefits of a fixed duration treatment for your patients and the treatment journey they may experience if prescribed VENCLEXTA, either in combination with obinutuzumab (1L CLL/SLL) or rituximab (R/R CLL).
Dosing Guide: 1L CLL, R/R CLL and AML
A summary of the different dosing regimens for VENCLEXTA across all indications, including recommended dose modifications, as well as details on risk assessment and prophylaxis for tumour lysis syndrome (TLS).
PATIENT RESOURCES
Patient information brochure for VENCLEXTA + obinutuzumab treatment (1L CLL)
Share this resource with your 1L CLL patients to help support them during VENCLEXTA + obinutuzumab treatment.
Patient Diary for 1L or R/R CLL
A short booklet designed to help patients understand their VENCLEXTA medication schedule. Includes a treatment diary for patients to fill in during the 5-week ramp-up period.
VENCLEXTA CONSUMER MEDICINES INFORMATION (CMI)
Download the CMI to provide your patients more information about VENCLEXTA.
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
1L: First-line. CLL: chronic lymphocytic leukaemia. CMI: Consumer Medicines Information. PBS: Pharmaceutical Benefits Scheme. PI: Product Information. TLS: tumour lysis syndrome.uMRD: undetectable minimal residual disease.
References: 1. VENCLEXTA Product Information.
AU-VENC-210040 Last revised September 2023